Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**7,12-dimethylbenz[a]anthracene (DMBA)** is a polycyclic aromatic hydrocarbon (PAH) that is a potent laboratory carcinogen[1][2][3]. DMBA is used in biomedical research to induce tumors, such as mammary and skin cancers in animal models, due to its ability to be metabolically activated by microsomal enzymes into diol epoxide intermediates, which covalently bind to DNA and initiate carcinogenesis[2]. It is found in tobacco smoke and is notable as a mutagen, teratogen, and flammable solid[1][2]. DMBA exhibits selectivity for necrosis and hemorrhaging in adrenal gland tissues and inhibits plasma alkaline phosphatase activity, likely through formation of charge transfer complexes with biomolecules[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7,12-dimethylbenz[a]anthracene.